HPC
CRSP icon

HM Payson & Co’s CRISPR Therapeutics CRSP Stock Holding History

HM Payson & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Sell
2,320
-1,000
-30% -$52.7K ﹤0.01% 526
2026
Q1 		$158K Buy
3,320
+1,000
+43% +$52.7K ﹤0.01% 477
2025
Q4 		$122K Hold
2,320
– – ﹤0.01% 520
2025
Q3 		$150K Sell
2,320
-10
-0.4% -$574 ﹤0.01% 487
2025
Q2 		$113K Hold
2,330
– – ﹤0.01% 517
2025
Q1 		$79.3K Hold
2,330
– – ﹤0.01% 561
2024
Q4 		$91.7K Hold
2,330
– – ﹤0.01% 545
2024
Q3 		$109K Buy
2,330
+1,250
+116% +$63.4K ﹤0.01% 510
2024
Q2 		$58.3K Hold
1,080
– – ﹤0.01% 574
2024
Q1 		$73.6K Buy
1,080
+100
+10% +$7.16K ﹤0.01% 547
2023
Q4 		$61.3K Hold
980
– – ﹤0.01% 556
2023
Q3 		$44.5K Hold
980
– – ﹤0.01% 602
2023
Q2 		$55K Hold
980
– – ﹤0.01% 562
2023
Q1 		$44.3K Hold
980
– – ﹤0.01% 596
2022
Q4 		$39.8K Buy
980
+500
+104% +$26.5K ﹤0.01% 587
2022
Q3 		$31K Buy
480
+400
+500% +$29K ﹤0.01% 635
2022
Q2 		$5K Hold
80
– – ﹤0.01% 883
2022
Q1 		$5K Hold
80
– – ﹤0.01% 908
2021
Q4 		$6K Sell
80
-25
-24% -$2.18K ﹤0.01% 919
2021
Q3 		$12K Buy
105
+28
+36% +$3.52K ﹤0.01% 815
2021
Q2 		$12K Buy
77
+42
+120% +$5.11K ﹤0.01% 803
2021
Q1 		$4K Buy
+35
New +$5.29K ﹤0.01% 963

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HM Payson & Co's CRSP Position: Q2 2026 in Review

HM Payson & Co reduced its CRISPR Therapeutics (CRSP) stake by 30% in Q2 2026, selling an estimated $52.7K and leaving 2,320 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #526.

HM Payson & Co first reported a position in CRSP in Q1 2021 and has held it in 22 quarters since. The position peaked at $158K in Q1 2026. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • HM Payson & Co held 2,320 shares of CRISPR Therapeutics worth $127K as of Q2 2026.
  • HM Payson & Co sold 1,000 CRISPR Therapeutics shares in Q2 2026, an estimated $52.7K.
  • CRISPR Therapeutics made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #526 holding.
  • HM Payson & Co first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • HM Payson & Co's CRISPR Therapeutics position peaked at $158K in Q1 2026.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.